Drug recall · November 4, 2026
Theophylline Extended-Release Tablets recall
Why: CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Theophylline Extended-Release Tablets, 100 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-500-10
- Lots / codes
Lot: 405617, Expiry: 03/31/2028
- Quantity
- 1,620 100-count bottles
- Company
- Brandywine Pharmaceuticals, LLC, West Chester, PA
- Distribution
- Nationwide within U.S
- Initiated
- October 6, 2026 · Voluntary: Firm initiated
- Classified
- October 29, 2026
- Reported
- November 4, 2026
- How notified
- Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Theophylline
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.